Publications by Waleed Ghanima
184 publications found
Original articles
Real-world Data on Treatment Patterns and Bleeding in Cancer-associated Thrombosis: Data from the TROLL Registry
TH Open, 8 (1), e132-e140
DOI 10.1055/s-0044-1782219, PubMed 38532938
Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia
Blood Adv (in press)
DOI 10.1182/bloodadvances.2023012044, PubMed 38386978
Risk of fractures and use of bisphosphonates in adult patients with immune thrombocytopenia-A nationwide population-based study
Br J Haematol (in press)
DOI 10.1111/bjh.19301, PubMed 38302094
Developing a machine learning model for bleeding prediction in patients with cancer-associated thrombosis receiving anticoagulation therapy
J Thromb Haemost, 22 (4), 1094-1104
DOI 10.1016/j.jtha.2023.12.034, PubMed 38184201
Cost-Effectiveness of Performing Reference Ultrasonography in Patients with Deep Vein Thrombosis
Thromb Haemost (in press)
DOI 10.1055/a-2213-9230, PubMed 37984402
The feasibility of self-performing measurements of peripheral oxygen saturation and respiratory exercises in home-isolated COVID-19 patients-a single-arm prospective trial
Pilot Feasibility Stud, 9 (1), 195
DOI 10.1186/s40814-023-01415-x, PubMed 38042811
Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study
Platelets, 34 (1), 2159019
DOI 10.1080/09537104.2022.2159019, PubMed 36636835
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial
Am J Hematol, 99 (1), 57-67
DOI 10.1002/ajh.27131, PubMed 38014779
Incidence of venous thromboembolism, recurrence, and bleeding after isolated superficial vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
J Thromb Haemost, 22 (2), 526-533
DOI 10.1016/j.jtha.2023.10.017, PubMed 37913911
Rilzabrutinib versus placebo in adults and adolescents with persistent or chronic immune thrombocytopenia: LUNA 3 phase III study
Ther Adv Hematol, 14, 20406207231205431
DOI 10.1177/20406207231205431, PubMed 37869360
Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism
Thromb Haemost, 124 (4), 351-362
DOI 10.1055/a-2188-8773, PubMed 37816388
Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis
Eur Heart J, 44 (32), 3073-3081
DOI 10.1093/eurheartj/ehad417, PubMed 37452732
Incidence and determinants of venous thromboembolism over 90 days in hospitalized and nonhospitalized patients with COVID-19
J Intern Med, 294 (6), 721-729
DOI 10.1111/joim.13706, PubMed 37518983
Incidence of bleeding and recurrence in isolated distal deep vein thrombosis: findings from the Venous Thrombosis Registry in Østfold Hospital
J Thromb Haemost, 21 (10), 2824-2832
DOI 10.1016/j.jtha.2023.06.028, PubMed 37394122
Does the clot burden as assessed by the Mean Bilateral Proximal Extension of the Clot score reflect mortality and adverse outcome after pulmonary embolism?
Acta Radiol Open, 12 (6), 20584601231187094
DOI 10.1177/20584601231187094, PubMed 37426515
Demographic, clinical, and echocardiographic factors associated with residual perfusion defects beyond six months after pulmonary embolism
Thromb Res, 229, 7-14
DOI 10.1016/j.thromres.2023.06.004, PubMed 37356172
Arterial events in cancer patients treated with apixaban for venous thrombosis
Thromb Res, 228, 128-133
DOI 10.1016/j.thromres.2023.05.017, PubMed 37327527
A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial
J Thromb Haemost, 21 (8), 2213-2222
DOI 10.1016/j.jtha.2023.04.045, PubMed 37230416
The Effects of Exercise Training in Patients With Persistent Dyspnea Following Pulmonary Embolism: A Randomized Controlled Trial
Chest, 164 (4), 981-991
DOI 10.1016/j.chest.2023.04.042, PubMed 37149257
Performance and Head-to-Head Comparison of Three Clinical Models to Predict Occurrence of Postthrombotic Syndrome: A Validation Study
Thromb Haemost, 123 (7), 692-699
DOI 10.1055/a-2039-3388, PubMed 36809776
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people
Res Pract Thromb Haemost, 7 (1), 100002
DOI 10.1016/j.rpth.2022.100002, PubMed 36448024
Measuring Quality of Life after Venous Thromboembolism: Who, When, and How?
Semin Thromb Hemost, 49 (8), 861-866
DOI 10.1055/s-0042-1754390, PubMed 36055276
Cognitive function in non-hospitalized patients 8-13 months after acute COVID-19 infection: A cohort study in Norway
PLoS One, 17 (8), e0273352
DOI 10.1371/journal.pone.0273352, PubMed 35994448
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study
Eur Heart J Qual Care Clin Outcomes, 8 (5), 577-587
DOI 10.1093/ehjqcco/qcab048, PubMed 34244745
The venous thrombosis registry in Østfold Hospital (TROLL registry) - design and cohort description
Res Pract Thromb Haemost, 6 (5)
DOI 10.1002/rth2.12770, PubMed 35949883
Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
Res Pract Thromb Haemost, 6 (5), e12748
DOI 10.1002/rth2.12748, PubMed 35992565
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia
N Engl J Med, 386 (15), 1421-1431
DOI 10.1056/NEJMoa2110297, PubMed 35417637
Effects of pulmonary rehabilitation on cardiac magnetic resonance parameters in patients with persistent dyspnea following pulmonary embolism
Int J Cardiol Heart Vasc, 40, 100995
DOI 10.1016/j.ijcha.2022.100995, PubMed 35345773
Prevention of post-thrombotic syndrome with rosuvastatin: A multicenter randomized controlled pilot trial (SAVER)
Thromb Res, 213, 119-124
DOI 10.1016/j.thromres.2022.03.014, PubMed 35344784
How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh)
J Patient Rep Outcomes, 6 (1), 24
DOI 10.1186/s41687-022-00429-y, PubMed 35303181
Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up
J Thromb Haemost, 20 (5), 1166-1181
DOI 10.1111/jth.15666, PubMed 35114046
Ruling out pulmonary embolism across different healthcare settings: A systematic review and individual patient data meta-analysis
PLoS Med, 19 (1), e1003905
DOI 10.1371/journal.pmed.1003905, PubMed 35077453
External Validation of the Patient-Reported Villalta Scale for the Diagnosis of Postthrombotic Syndrome
Thromb Haemost, 122 (8), 1379-1383
DOI 10.1055/a-1738-1313, PubMed 35021257
Association between myocardial fibrosis, as assessed with cardiac magnetic resonance T1 mapping, and persistent dyspnea after pulmonary embolism
Int J Cardiol Heart Vasc, 38, 100935
DOI 10.1016/j.ijcha.2021.100935, PubMed 35005213
Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia
Adv Ther, 38 (12), 5791-5808
DOI 10.1007/s12325-021-01934-0, PubMed 34704193
Statins for venous event reduction in patients with venous thromboembolism: A multicenter randomized controlled pilot trial assessing feasibility
J Thromb Haemost, 20 (1), 126-132
DOI 10.1111/jth.15537, PubMed 34564938
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune Thrombocytopenia
Clin Pharmacol Ther, 110 (6), 1570-1578
DOI 10.1002/cpt.2399, PubMed 34416023
Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome
Thromb Res, 206, 66-75
DOI 10.1016/j.thromres.2021.08.012, PubMed 34419865
Patient outcomes after electrical injury - a retrospective study
Scand J Trauma Resusc Emerg Med, 29 (1), 114
DOI 10.1186/s13049-021-00920-3, PubMed 34362435
Post-thrombotic syndrome in patients with venous thromboembolism treated with dabigatran or warfarin: A long-term cross-sectional follow-up of RE-COVER study patients
J Thromb Haemost, 19 (10), 2495-2503
DOI 10.1111/jth.15449, PubMed 34255420
Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI)
Br J Haematol, 194 (4), 759-766
DOI 10.1111/bjh.17694, PubMed 34263940
Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
Res Pract Thromb Haemost, 5 (5), e12566
DOI 10.1002/rth2.12566, PubMed 34278193
Detection of upper extremity deep vein thrombosis by magnetic resonance non-contrast thrombus imaging
J Thromb Haemost, 19 (8), 1973-1980
DOI 10.1111/jth.15394, PubMed 34018662
Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Time Trends and Treatment Patterns
Clin Ther, 43 (7), 1179-1190.e3
DOI 10.1016/j.clinthera.2021.04.017, PubMed 34083030
Incidence of thrombotic complications in hospitalised and non-hospitalised patients after COVID-19 diagnosis
Br J Haematol, 194 (3), 542-546
DOI 10.1111/bjh.17522, PubMed 34028814
How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment
Blood, 137 (20), 2736-2744
DOI 10.1182/blood.2021010968, PubMed 33827138
An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination
J Thromb Haemost, 19 (7), 1813-1818
DOI 10.1111/jth.15352, PubMed 33909350
Effectiveness and safety of oral anticoagulants in elderly patients with atrial fibrillation
Heart, 108 (5), 345-352
DOI 10.1136/heartjnl-2020-318753, PubMed 33975877
Predictors for and outcomes after bone marrow biopsy in Scandinavian patients with chronic immune thrombocytopenia
Eur J Haematol, 107 (1), 145-156
DOI 10.1111/ejh.13635, PubMed 33851445
Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis
Blood Adv, 5 (5), 1369-1378
DOI 10.1182/bloodadvances.2020003849, PubMed 33661297
Prevalence and Risk Factors for Post-Traumatic Stress in Hospitalized and Non-Hospitalized COVID-19 Patients
Int J Environ Res Public Health, 18 (4)
DOI 10.3390/ijerph18042079, PubMed 33672759
Pulmonary and cardiac variables associated with persistent dyspnea after pulmonary embolism
Thromb Res, 201, 90-99
DOI 10.1016/j.thromres.2021.02.014, PubMed 33662800
Prevalence and Determinants of Fatigue after COVID-19 in Non-Hospitalized Subjects: A Population-Based Study
Int J Environ Res Public Health, 18 (4)
DOI 10.3390/ijerph18042030, PubMed 33669714
Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study
Blood, 136 (26), 3056-3061
DOI 10.1182/blood.2020007594, PubMed 32814348
Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life
Am J Hematol, 96 (2), 199-207
DOI 10.1002/ajh.26036, PubMed 33107998
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment
Am J Hematol, 96 (2), 188-198
DOI 10.1002/ajh.26045, PubMed 33170956
70 patients with COVID-19 admitted to Ostfold Hospital
Tidsskr. Nor. Laegeforen., 140 (18), 1885-1890
Seventy patients treated for COVID-19 by Østfold Hospital Trust
Tidsskr Nor Laegeforen, 140 (18)
DOI 10.4045/tidsskr.20.0612, PubMed 33322876
Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study
Thorax, 76 (4), 405-407
DOI 10.1136/thoraxjnl-2020-216377, PubMed 33273028
Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis
Blood Adv, 4 (20), 5002-5010
DOI 10.1182/bloodadvances.2020002173, PubMed 33057634
The mean bilateral proximal extension of the clot is associated with pulmonary embolism severity parameters and management-associated outcomes
Acta Radiol, 62 (10), 1309-1316
DOI 10.1177/0284185120966724, PubMed 33100028
[Thromboprophylaxis for patients with COVID-19 infection]
Tidsskr Nor Laegeforen, 140 (13)
DOI 10.4045/tidsskr.20.0603, PubMed 32998497
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Thromb Res, 196, 238-244
DOI 10.1016/j.thromres.2020.08.042, PubMed 32919178
Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia
Br J Haematol, 190 (6), 933-938
DOI 10.1111/bjh.16959, PubMed 33439486
Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
J Thromb Haemost, 18 (9), 2341-2348
DOI 10.1111/jth.14986, PubMed 32613731
Intensification of antithrombotic therapy for chronic atherosclerosis
Tidsskr Nor Laegeforen, 140 (10)
DOI 10.4045/tidsskr.20.0066, PubMed 32602309
Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis
Blood Adv, 4 (11), 2468-2476
DOI 10.1182/bloodadvances.2020001556, PubMed 32502267
Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study
Br J Haematol, 191 (3), 460-465
DOI 10.1111/bjh.16672, PubMed 32342497
D-dimer as a stand-alone test to rule out deep vein thrombosis
Thromb Res, 191, 134-139
DOI 10.1016/j.thromres.2020.04.026, PubMed 32447095
Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis
Blood, 135 (16), 1377-1385
DOI 10.1182/blood.2019004114, PubMed 32016390
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Eur Heart J Cardiovasc Pharmacother, 6 (2), 75-85
DOI 10.1093/ehjcvp/pvz086, PubMed 31942972
Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale
Thromb Res, 190, 45-51
DOI 10.1016/j.thromres.2020.03.020, PubMed 32298840
Fatigue after initiating rivaroxaban for venous thromboembolism
Res Pract Thromb Haemost, 4 (4), 582-585
DOI 10.1002/rth2.12312, PubMed 32548556
[Correction: Home treatment for pulmonary embolism]
Tidsskr Nor Laegeforen, 140 (4)
DOI 10.4045/tidsskr.20.0116, PubMed 32192270
Home treatment for pulmonary embolism
Tidsskr. Nor. Laegeforen., 139 (18), 1768-1774
[Home treatment for pulmonary embolism]
Tidsskr Nor Laegeforen, 139 (18)
DOI 10.4045/tidsskr.19.0115, PubMed 31823570
Routine clinical care for chronic immune thrombocytopenia purpura in Denmark, 2009-2015
Hematology, 24 (1), 732-736
DOI 10.1080/16078454.2019.1685739, PubMed 31674882
Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists
Thromb Res, 185, 119-124
DOI 10.1016/j.thromres.2019.11.031, PubMed 31805421
Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?
Platelets, 31 (7), 906-912
DOI 10.1080/09537104.2019.1696456, PubMed 31762368
Initiation of statins and risk of venous thromboembolism: Population-based matched cohort study
Thromb Res, 184, 99-104
DOI 10.1016/j.thromres.2019.11.003, PubMed 31715545
Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms - Impact Of Comorbidity
Clin Epidemiol, 11, 955-967
DOI 10.2147/CLEP.S216787, PubMed 31807079
Gastric sleeve resection as day-case surgery: what affects the discharge time?
Surg Obes Relat Dis, 15 (12), 2018-2024
DOI 10.1016/j.soard.2019.09.070, PubMed 31699651
Risk factors for symptomatic venous thromboembolism following surgery for closed ankle fractures: A case-control study
Foot Ankle Surg, 26 (6), 681-686
DOI 10.1016/j.fas.2019.08.006, PubMed 31481323
Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim
EClinicalMedicine, 14, 80-87
DOI 10.1016/j.eclinm.2019.07.015, PubMed 31709405
Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists
Platelets, 31 (3), 322-328
DOI 10.1080/09537104.2019.1639655, PubMed 31280643
Pain and nausea after bariatric surgery with total intravenous anesthesia versus desflurane anesthesia: a double blind, randomized, controlled trial
Surg Obes Relat Dis, 15 (9), 1505-1512
DOI 10.1016/j.soard.2019.05.010, PubMed 31227317
Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia
J Thromb Haemost, 17 (6), 912-924
DOI 10.1111/jth.14446, PubMed 30933417
Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists
Platelets, 31 (2), 198-205
DOI 10.1080/09537104.2019.1585527, PubMed 30885035
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group
Eur J Haematol, 102 (3), 235-240
DOI 10.1111/ejh.13198, PubMed 30472746
New score for assessing bleeding risk in patients with atrial fibrillation treated with NOACs
Open Heart, 5 (2), e000931
DOI 10.1136/openhrt-2018-000931, PubMed 30613418
Safety of D-dimer testing as a stand-alone test for the exclusion of deep vein thrombosis as compared with other strategies
J Thromb Haemost, 16 (12), 2471-2481
DOI 10.1111/jth.14314, PubMed 30303610
The impact of post-pulmonary embolism syndrome and its possible determinants
Thromb Res, 171, 84-91
DOI 10.1016/j.thromres.2018.09.048, PubMed 30267974
Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists
Eur J Haematol, 100 (5), 475-478
DOI 10.1111/ejh.13043, PubMed 29427461
Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms
Eur J Haematol, 100 (5), 419-425
DOI 10.1111/ejh.13034, PubMed 29369421
[Antidote treatment during use of direct anticoagulants]
Tidsskr Nor Laegeforen, 138 (3)
DOI 10.4045/tidsskr.17.0190, PubMed 29411596
Rivaroxaban versus warfarin for the prevention of post-thrombotic syndrome
Thromb Res, 163, 6-11
DOI 10.1016/j.thromres.2018.01.013, PubMed 29324334
A man in the 50s with fever and anaemia
Tidsskr. Nor. Laegeforen., 138 (2), 148-152
Immune thrombocytopenia is associated with persistently deranged fibrosis-related seromarker profiles but low bone marrow fibrosis grades: A 2-year observational study on thrombopoietin receptor agonist treatment
Platelets, 30 (2), 222-228
DOI 10.1080/09537104.2017.1411586, PubMed 29293383
Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia
Platelets, 30 (2), 206-212
DOI 10.1080/09537104.2017.1394451, PubMed 29215956
JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR
Int J Lab Hematol, 40 (2), 181-186
DOI 10.1111/ijlh.12762, PubMed 29150911
Diagnostic scales for the post-thrombotic syndrome
Thromb Res, 164, 110-115
DOI 10.1016/j.thromres.2017.10.022, PubMed 29126608
Evaluating patient experiences in decentralised acute care using the Picker Patient Experience Questionnaire; methodological and clinical findings
BMC Health Serv Res, 17 (1), 685
DOI 10.1186/s12913-017-2614-4, PubMed 28962561
Late consequences of venous thromboembolism: Measuring quality of life after deep vein thrombosis and pulmonary embolism
Thromb Res, 164, 170-176
DOI 10.1016/j.thromres.2017.07.025, PubMed 28760416
Risk of cardiovascular events and pulmonary hypertension following splenectomy - a Danish population-based cohort study from 1996-2012
Haematologica, 102 (8), 1333-1341
DOI 10.3324/haematol.2016.157008, PubMed 28572164
Scoring Systems for Postthrombotic Syndrome
Semin Thromb Hemost, 43 (5), 500-504
DOI 10.1055/s-0037-1599142, PubMed 28470653
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years
Hematol Oncol, 36 (1), 217-223
DOI 10.1002/hon.2415, PubMed 28393375
Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP)
Platelets, 28 (5), 478-483
DOI 10.1080/09537104.2016.1235691, PubMed 27819522
Health-related quality of life after pulmonary embolism: a cross-sectional study
BMJ Open, 6 (11), e013086
DOI 10.1136/bmjopen-2016-013086, PubMed 27810979
New anticoagulants in combination with antiplatelet agents
Tidsskr Nor Laegeforen, 136 (18), 1543-1546
DOI 10.4045/tidsskr.15.1356, PubMed 27731598
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
Eur Heart J Cardiovasc Pharmacother, 3 (1), 28-36
DOI 10.1093/ehjcvp/pvw031, PubMed 27680880
Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway
Eur J Haematol, 98 (1), 85-93
DOI 10.1111/ejh.12788, PubMed 27500783
A qualitative study of patient experiences of decentralized acute healthcare services
Scand J Prim Health Care, 34 (3), 317-24
DOI 10.1080/02813432.2016.1222200, PubMed 27559763
General practitioners' perspectives on referring patients to decentralized acute health care
Fam Pract, 33 (6), 709-714
DOI 10.1093/fampra/cmw087, PubMed 27543796
Health-related quality of life after deep vein thrombosis
Springerplus, 5 (1), 1278
DOI 10.1186/s40064-016-2949-z, PubMed 27547653
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Leuk Lymphoma, 58 (3), 623-632
DOI 10.1080/10428194.2016.1204653, PubMed 27389974
Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial
Lancet Haematol, 3 (2), e64-71
DOI 10.1016/S2352-3026(15)00248-3, PubMed 26853645
Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome
Thromb Haemost, 115 (2), 361-367
DOI 10.1160/th15-04-0318, PubMed 26422814
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Lancet, 385 (9978), 1653-61
DOI 10.1016/S0140-6736(14)61495-1, PubMed 25662413
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis
Lancet Haematol, 2 (2), e75-81
DOI 10.1016/S2352-3026(15)00003-4, PubMed 26687612
Quality of life after pulmonary embolism: first cross-cultural evaluation of the pulmonary embolism quality-of-life (PEmb-QoL) questionnaire in a Norwegian cohort
Qual Life Res, 24 (2), 417-25
DOI 10.1007/s11136-014-0779-4, PubMed 25120017
Pain and bleeding associated with trephine biopsy
Eur J Haematol, 93 (4), 267-72
DOI 10.1111/ejh.12339, PubMed 24725088
Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration
Haematologica, 99 (7), 1264-71
DOI 10.3324/haematol.2013.103291, PubMed 24747949
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up
Haematologica, 99 (5), 937-44
DOI 10.3324/haematol.2013.098921, PubMed 24463212
Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura
J Thromb Haemost, 10 (8), 1616-23
DOI 10.1111/j.1538-7836.2012.04757.x, PubMed 22537155
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
Lancet, 379 (9810), 31-8
DOI 10.1016/S0140-6736(11)61753-4, PubMed 22172244
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents
Br J Haematol, 155 (2), 248-55
DOI 10.1111/j.1365-2141.2011.08845.x, PubMed 21902682
Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is associated with bone marrow hypercellularity and mild reticulin fibrosis but not other stromal abnormalities
Mod Pathol, 25 (1), 65-74
DOI 10.1038/modpathol.2011.128, PubMed 21841770
Thrombopoietic agents in immune thrombocytopenia
Semin Hematol, 47 (3), 258-65
DOI 10.1053/j.seminhematol.2010.03.003, PubMed 20620437
Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency
J Thromb Haemost, 7 (8), 1268-75
DOI 10.1111/j.1538-7836.2009.03464.x, PubMed 19422443
Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771)
Am Heart J, 154 (5), 808-14
DOI 10.1016/j.ahj.2007.07.010, PubMed 17967583
Multidetector computed tomography (MDCT) in the diagnosis of pulmonary embolism: interobserver agreement among radiologists with varied levels of experience
Acta Radiol, 48 (2), 165-70
DOI 10.1080/02841850601100859, PubMed 17354136
The association between the proximal extension of the clot and the severity of pulmonary embolism (PE): a proposal for a new radiological score for PE
J Intern Med, 261 (1), 74-81
DOI 10.1111/j.1365-2796.2006.01733.x, PubMed 17222170
Validation of a new D-dimer microparticle enzyme immunoassay (AxSYM D-Dimer) in patients with suspected pulmonary embolism (PE)
Thromb Res, 120 (4), 471-6
DOI 10.1016/j.thromres.2006.11.005, PubMed 17161451
D-dimer level is associated with the extent of pulmonary embolism
Thromb Res, 120 (2), 281-8
DOI 10.1016/j.thromres.2006.08.006, PubMed 17030057
Primary chronic cold agglutinin disease: a population based clinical study of 86 patients
Haematologica, 91 (4), 460-6
PubMed 16585012
The performance of STA-Liatest D-dimer assay in out-patients with suspected pulmonary embolism
Br J Haematol, 132 (2), 210-5
DOI 10.1111/j.1365-2141.2005.05859.x, PubMed 16398655
Management of suspected pulmonary embolism (PE) by D-dimer and multi-slice computed tomography in outpatients: an outcome study
J Thromb Haemost, 3 (9), 1926-32
DOI 10.1111/j.1538-7836.2005.01544.x, PubMed 16102097
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia
Eur J Haematol, 72 (6), 441-3
DOI 10.1111/j.1600-0609.2004.00257.x, PubMed 15128424
Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients
Blood, 103 (8), 2925-8
DOI 10.1182/blood-2003-10-3597, PubMed 15070665
[Hairy cell leukemia treated with cladribine]
Tidsskr Nor Laegeforen, 122 (11), 1094-7
PubMed 12043051
[Time delay in the thrombolytic treatment of myocardial infarction]
Tidsskr Nor Laegeforen, 120 (16), 1851-3
PubMed 10925610
Review articles
Risk-based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP)
Eur J Haematol, 112 (4), 504-515
DOI 10.1111/ejh.14154, PubMed 38088207
Refractory immune thrombocytopenia in adults: Towards a new definition
Br J Haematol, 203 (1), 23-27
DOI 10.1111/bjh.19075, PubMed 37642211
Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib
Platelets, 34 (1), 2131751
DOI 10.1080/09537104.2022.2131751, PubMed 36331249
Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives
Ther Clin Risk Manag, 18, 273-286
DOI 10.2147/TCRM.S251672, PubMed 35386180
Safety and Efficiency of Diagnostic Strategies for Ruling Out Pulmonary Embolism in Clinically Relevant Patient Subgroups : A Systematic Review and Individual-Patient Data Meta-analysis
Ann Intern Med, 175 (2), 244-255
DOI 10.7326/M21-2625, PubMed 34904857
Health-related quality-of-life questionnaires for deep vein thrombosis and pulmonary embolism: A systematic review on questionnaire development and methodology
Res Pract Thromb Haemost, 5 (5), e12556
DOI 10.1002/rth2.12556, PubMed 34278190
Immune Thrombocytopenia (ITP): Current Limitations in Patient Management
Medicina (Kaunas), 56 (12)
DOI 10.3390/medicina56120667, PubMed 33266286
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Blood Adv, 3 (22), 3780-3817
DOI 10.1182/bloodadvances.2019000812, PubMed 31770441
Immune Thrombocytopenia
N Engl J Med, 381 (10), 945-955
DOI 10.1056/NEJMcp1810479, PubMed 31483965
Thrombopoietin receptor agonists: ten years later
Haematologica, 104 (6), 1112-1123
DOI 10.3324/haematol.2018.212845, PubMed 31073079
Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants
Scand Cardiovasc J, 52 (3), 156-162
DOI 10.1080/14017431.2018.1453613, PubMed 29569500
New oral anticoagulants--a review
Tidsskr Nor Laegeforen, 133 (18), 1940-5
DOI 10.4045/tidsskr.12.1111, PubMed 24084970
[Primary myelofibrosis--pathogenesis, diagnosis and treatment]
Tidsskr Nor Laegeforen, 133 (18), 1946-50
DOI 10.4045/tidsskr.12.1106, PubMed 24084971
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment
Blood, 120 (5), 960-9
DOI 10.1182/blood-2011-12-309153, PubMed 22740443
[Immune thrombocytopenia--pathophysiology and treatment]
Tidsskr Nor Laegeforen, 130 (21), 2120-3
DOI 10.4045/tidsskr.09.1119, PubMed 21052113
Other articles
ITP definitions: Time for an update
Br J Haematol, 201 (5), 1005-1006
DOI 10.1111/bjh.18791, PubMed 37004991
Low D-dimer levels at diagnosis of venous thromboembolism are associated with reduced risk of recurrence: data from the TROLL registry
J Thromb Haemost, 21 (7), 1861-1868
DOI 10.1016/j.jtha.2023.03.026, PubMed 37004791
[Factor Xa inhibitors in the prevention and treatment of venous thromboembolism in cancer patients]
Tidsskr Nor Laegeforen, 142 (1)
DOI 10.4045/tidsskr.22.0228, PubMed 36655971
"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up": Reply
J Thromb Haemost, 20 (8), 1937-1939
DOI 10.1111/jth.15774, PubMed 35859282
The effect of rivaroxaban on the diagnostic value of D-dimer in patients with suspected deep vein thrombosis
Thromb Res, 216, 22-24
DOI 10.1016/j.thromres.2022.05.017, PubMed 35687980
Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network
Br J Haematol, 197 (5), 633-638
DOI 10.1111/bjh.18111, PubMed 35303315
Mycophenolate Mofetil for Immune Thrombocytopenia
N Engl J Med, 385 (23), 2200-2201
DOI 10.1056/NEJMc2115772, PubMed 34874642
Subacute thyroiditis after COVID-19
Tidsskr Nor Laegeforen, 141 (10)
DOI 10.4045/tidsskr.21.0169, PubMed 34182720
Quality of life after COVID-19 without hospitalisation: Good overall, but reduced in some dimensions
J Infect, 82 (5), 186-230
DOI 10.1016/j.jinf.2021.01.002, PubMed 33434590
Pulmonary rehabilitation to improve physical capacity, dyspnea, and quality of life following pulmonary embolism (the PeRehab study): study protocol for a two-center randomized controlled trial
Trials, 22 (1), 22
DOI 10.1186/s13063-020-04940-9, PubMed 33407792
Thrombosis prophylaxis in patients with covid-19 infection
Tidsskr. Nor. Laegeforen., 140 (13), 1319-1320
Incidence and prevalence of venous thromboembolism in Norway 2010-2017
Thromb Res, 195, 165-168
DOI 10.1016/j.thromres.2020.07.011, PubMed 32707359
Intensification of antithrombotic therapy for chronic atherosclerosis
Tidsskr. Nor. Laegeforen., 140 (10), 976-977
Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases
Thromb Res, 194, 116-118
DOI 10.1016/j.thromres.2020.06.032, PubMed 32788102
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease (vol 381, pg 1820, 2019)
N. Engl. J. Med., 382 (11), 1078
DOI 10.1056/NEJMx200004
Immune Thrombocytopenia. Reply
N Engl J Med, 382 (11), 1077-1078
DOI 10.1056/NEJMc1913324, PubMed 32160681
Adverse drug reactions upon use of new anticoagulants
Tidsskr Nor Laegeforen, 138 (12)
DOI 10.4045/tidsskr.18.0566, PubMed 30132601
Adverse drug reactions upon use of new anticoagulants
Tidsskr. Nor. Laegeforen., 138 (12), 1099-1100
[Not Available]
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0238, PubMed 29663755
Serum concentration measurements of DOAK drugs Reply
Tidsskr. Nor. Laegeforen., 138 (7), 621
[A man in his 50s with fever and anemia]
Tidsskr Nor Laegeforen, 138 (2)
DOI 10.4045/tidsskr.17.0460, PubMed 29357654
[New direct-acting anticoagulants for cancer patients?]
Tidsskr Nor Laegeforen, 137 (3), 171-172
DOI 10.4045/tidsskr.17.0008, PubMed 28181748
Response of first line treatment with corticosteroids in a population-based cohort of adults with primary immune thrombocytopenia
Eur J Intern Med, 37, e23-e25
DOI 10.1016/j.ejim.2016.09.001, PubMed 27633568
Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study
Br J Haematol, 174 (4), 639-42
DOI 10.1111/bjh.13787, PubMed 26456477
Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists
Br J Haematol, 158 (6), 811-4
DOI 10.1111/j.1365-2141.2012.09227.x, PubMed 22816787
Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis
J Thromb Haemost, 9 (6), 1261-3
DOI 10.1111/j.1538-7836.2011.04298.x, PubMed 21489133
Risk stratification of pulmonary embolism by computed tomography
J Intern Med, 262 (6), 702
DOI 10.1111/j.1365-2796.2007.1858.x, PubMed 17944881
Theses
The role of D-dimer and multi-detector computed tomography in the management of pulmonary embolism
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 529, 1 b. (flere pag.)
BIBSYS 071007342, ISBN 978-82-8072-864-7